IQVIA Backs New Real-World Eczema Study, Adding Momentum to Dermatology Data Plays

IQVIA Holdings (IQV) announced an update on their ongoing clinical study.

The study “Prospective, Non-interventional, Multicenter Real-world Evidence Study on Effectiveness and Safety of Treatment of Patients With Moderate to Severe Chronic Hand Eczema With Delgocitinib Cream (20mg/g)” tracks how adults respond to a new cream in everyday care. It aims to show if the treatment works and is safe in real clinics, which matters for doctors, payers, and investors watching dermatology growth.

The treatment is delgocitinib cream, a topical drug used on the skin for chronic hand eczema. It is meant to reduce redness, cracking, and itching in patients whose disease is moderate to severe and often hard to control.

This is an observational study, so doctors choose the cream as part of routine care and patients are simply followed over time. There is no random assignment or placebo; researchers just record outcomes in a large group to see how the drug performs in the real world.

The study runs prospectively, meaning patients are tracked forward from the time they start treatment and their progress is measured over 52 weeks. The main goal is to see how many reach clear or almost clear skin by a doctor’s rating scale, while also watching for safety issues over the year.

The trial was first submitted on May 7, 2026, marking the formal launch of data collection planning. The most recent update on May 19, 2026 confirms the design and status, giving investors fresh visibility into operational progress.

The study is currently “enrolling by invitation,” meaning sites are selecting suitable adults with moderate to severe disease. Primary and final completion dates are not posted yet, but the planned 52-week follow-up suggests meaningful readouts are likely roughly one to two years after full enrollment.

For investors, this update highlights growing real-world evidence around delgocitinib that could support stronger uptake if results are positive. Better long-term safety and effectiveness data can help drive higher prescriptions, tighter reimbursement, and potential label or guideline support in key markets.

LEO Pharma leads the study, with support from Optimapharm, ICON, IQVIA Inc., and Vivactis M2Research, underscoring the role of contract research and data firms in dermatology. For IQV (IQV), ongoing involvement in large real-world programs can reinforce its reputation in evidence generation, a key growth area versus peers like ICON and Syneos.

Stronger real-world data can also help delgocitinib compete against existing topical steroids and newer targeted creams, supporting the broader eczema treatment market. If outcomes are strong, sentiment may improve not only toward LEO’s asset but also toward service providers like IQVIA that enable faster, higher-quality evidence packages.

The study remains active and updated, with more detailed information and future data releases available on the ClinicalTrials portal.

To learn more about IQV’s potential, visit the IQVIA Holdings drug pipeline page.